H.C. Wainwright lowered the firm’s price target on I-Mab (IMAB) to $7 from $8 and keeps a Buy rating on the shares. The company continues to move forward with a more focused strategy as a U.S.-based biotech, the analyst tells investors in a research note. The firm views I-Mab as “greatly underappreciated given the clinical promise of its assets.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue